Survival figures for rectal cancer on the increase, but centralisation remains crucial

5 May 2021

In Flanders, the survival figures of patients with rectal cancer are of the highest in Europe. But figures can be improved still. Leuven doctors warn that there are still big differences in the results between hospitals and push for more centralisation via a volume standard. This is a required minimum number of patients a hospital has to treat annually to be able to provide the best quality care.

Operatie bij rectumkanker

More than 50 Flemish hospitals reported their mortality and survival figures for all patients with rectal cancer treated between 2015 and 2017. In comparison to the previous report of four years ago, the resultt after rectal cancer treatment continue to improve. There are however big differences between the different Flemish hospitals. Annually UZ Leuven treats the largest number of patients and is at the same time able to present the best survival rates.

Chances of survival continue to increase

For patients undergoing a surgical treatment at UZ Leuven, mortality rates within 30 days post-surgery came down from 0.7% to 0.4%. The 90-day mortality came down even more, from 1% to 0.4%. With this, UZ Leuven does significantly better than the Flemish average.

Prof. dr. André D’Hoore, head of the abdominal surgery department at UZ Leuven: “The last couple of years the mortality risk of all UZ Leuven patients undergoing surgery has dropped significantly. And this despite the fact that our patients are much older, and also suffer from other diseases such as diabetes and cardiovascular disorders.”

The survival rates five years after the rectal cancer diagnosis are also 10% better at UZ Leuven than the average of all Flemish hospitals. For patients that underwent surgery at UZ Leuve, the chance of survival after three years is 93,6% and after five years 80%.

Need for a volume standard

Because the treatment for rectal cancer is complex and multidisciplinary, hospitals need to follow a sufficient number of patients to create, measure and, if necessary, adjust the quality of care.

Prof. dr. D’Hoore: “It is remarkable to see that more than half of all Flemish hospitals treat so few patients with rectal cancer annually that they can't provide reliable survival rates. This makes quality control difficult. Experts have been recommending a volume standard for some time, requiring each hospital to follow a minimum number of patients annually, as is already the case in several countries. Such a volume standard can for example be imposed by the government or can be agreed within hospital networks.”

The last couple of years the mortality risk of patients undergoing surgery for rectal cancer at UZ Leuven has dropped spectacularly.
Prof. dr. André D'Hoore, head of the abdominal surgery department at UZ Leuven

Innovative and multidisciplinary approach

Rectal cancer requires a complex and multidisciplinary treatment. Firstly, the multidisciplinary team determines, via various tests, whether the patient is best helped with immediate surgery or whether chemotherapy and/or radiotherapy is recommended.

Prof. dr. D’Hoore: “The abdominal surgery department has played a pioneering role in developing minimal transanal surgery, as a result of which rectal tumours can be removed in a less invasive manner.”

The surgical procedure may be the most important, but is still only one part of the treatment programme for rectal cancer. Prof. dr. Albert Wolthuis, abdominal and colorectal surgeon: “We can see that post-operative mortality is mostly due to a failure to rescue in case of complications.”

Prof. dr. Eric Van Cutsem, head of the digestive oncology department at UZ Leuven: “For the follow-up after the surgical procedure and most definitely also for setting up the treatment strategy, a strong multidisciplinary team is crucial. Our excellent results are a reflection of the expertise and efforts of the whole team, consisting of doctors, nurses, colostomy nurses, nursing specialists, physiotherapists ...”

The Flemish Institute for Quality of Care (VIKZ) collects all data of the participating hospitals and makes them available on There you can find an interpretation and figures can be compared.

More about "General medical oncology"

First proven medicine for aggressive desmoid tumours

24 March 2023
Leuven researchers collaborated on a brand new gamma-secretase inhibitor for rare connective tissue tumours. "It is the first time that we were able to find a medicine against aggressive desmoid tumours with convincing clinical evidence."
More info
More about "Abdominal surgery"

Higher survival rate pancreatic cancer after minimally invasive surgery

10 January 2023
UZ Leuven doctors compared the survival rate of patients with pancreatic cancer after minimally invasive surgery versus classic open abdominal surgery. Their conclusion is clear: patients treated with minimally invasive surgery have a better longterm survival rate and are less likely to relapse.
More info
More about "Abdominal surgery"

Minimally invasive keyhole operation is the future of complex pancreatic surgery

28 June 2019
From 1 July 2019 UZ Leuven will be a recognised centre of expertise for complex pancreatic surgery. In 2018, UZ Leuven performed 153 pancreatic operations of the most complex type, which made Leuven the only centre to handle more than 100 complex pancreatic operations that year.
More info
Last edit: 18 May 2021